Cor Vasa 2013, 55(2):e95-e100 | DOI: 10.1016/j.crvasa.2013.03.002

Stroke prevention in patients with atrial fibrillation - anticoagulation strategy 2012

Marcin Syzdół*, Michał Tendera
3rd Division of Cardiology, Medical University of Silesia, Katowice, Poland

Vitamin K antagonists have been recommended as the only available oral anticoagulants for stroke prevention in patients with atrial fibrillation for many years. Despite their proved effectiveness, there are several limitations and drawbacks of this therapy. Recently three major clinical trials of novel oral anticoagulants clinical trials have been published. Dabigatran, a direct thrombin inhibitor, as well as rivaroxaban and apixaban, direct Xa factor inhibitors, were found to have at least non-inferior efficacy and safety in comparison to vitamin K antagonists for stroke prevention in patients with non-valvular fibrillation. These novel oral anticoagulants may constitute a valuable alternative to vitamin K antagonists.

Keywords: Apixaban; Atrial fibrillation; Dabigatran; Rivaroxaban; Stroke prevention

Received: November 24, 2012; Accepted: March 1, 2013; Published: April 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Syzdół M, Tendera M. Stroke prevention in patients with atrial fibrillation - anticoagulation strategy 2012. Cor Vasa. 2013;55(2):e95-100. doi: 10.1016/j.crvasa.2013.03.002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. P.A. Wolf, R.D. Abbott, W.B. Kannel, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke 22 (1991) 983-988. Go to original source... Go to PubMed...
    2. C. Marini, F. De Santis, S. Sacco, et al., Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study, Stroke 36 (2005) 1115-1119. Go to original source... Go to PubMed...
    3. A.J. Camm, P. Kirchhof, G.Y.H. Lipp, et al., Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), European Heart Journal 31 (2010) 2369-2429.
    4. R.G. Hart, L.A. Pearce, M.I. Aguilar, et al., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Annals of Internal Medicine 146 (2007) 857-867. Go to original source... Go to PubMed...
    5. E.M. Hylek, S.J. Skates, M.A. Sheehan, et al., An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation, The New England Journal of Medicine 335 (1996) 540-546. Go to original source... Go to PubMed...
    6. J. Mant, F.D. Hobbs, K. Fletcher, et al., Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial, Lancet 370 (2007) 493-503. Go to original source... Go to PubMed...
    7. S.J. Connolly, J. Pogue, J. Eikelboom, et al., Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range, Circulation 11 (2008) 2029-2037. Go to original source... Go to PubMed...
    8. D.B. Matchar, G.P. Samsa, S.J. Cohen, et al., Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial, American Journal of Medicine 113 (2002) 42-51. Go to original source... Go to PubMed...
    9. S. Blech, T. Ebner, E. Ludwig-Schwellinger, et al., The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans, Drug Metabolism and Disposition 36 (2008) 386-399. Go to original source... Go to PubMed...
    10. J. Stangier, K. Rathgen, H. Stähle, et al., The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects, British Journal of Clinical Pharmacology 64 (2007) 292-303. Go to original source... Go to PubMed...
    11. K.H. Liesenfeld, T. Lehr, C. Dansirikul, et al., Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial, Journal of Thrombosis and Haemostasis 11 (2011) 2168-2175. Go to original source... Go to PubMed...
    12. S.J Connolly, M.D. Ezekowitz, S. Yusuf, et al., Dabigatran versus warfarin in patients with atrial fibrillation, The New England Journal of Medicine 361 (2009) 1139-1151. Go to original source... Go to PubMed...
    13. S.J Connolly, M.D. Ezekowitz, S. Yusuf, et al., Newly identified events in the RE-LY trial, The New England Journal of Medicine 363 (2010) 1875-1876. Go to original source... Go to PubMed...
    14. J.W. Eikelboom, L. Wallentin, S.J. Connolly, et al., Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial, Circulation 123 (2011) 2363-2372. Go to original source... Go to PubMed...
    15. L. Wallentin, S. Yusuf, M.D. Ezekowitz, et al., Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial, Lancet 376 (2010) 975-983. Go to original source... Go to PubMed...
    16. H.C. Diener, S.J. Connolly, M.D. Ezekowitz, et al., Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischemic attack or stroke: a subgroup analysis of the RE-LY trial, Lancet Neurology 9 (2010) 1157-1163. Go to original source... Go to PubMed...
    17. M.D. Ezekowitz, L. Wallentin, S.J. Connolly, et al., Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation, Circulation 122 (2010) 2246-2253. Go to original source... Go to PubMed...
    18. R. Nagarakanti, M.D. Ezekowitz, J. Oldgren, et al., Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion, Circulation 123 (2011) 131-136. Go to original source... Go to PubMed...
    19. E. Perzborn, S. Roehrig, A. Straub, et al., Rivaroxaban: a new oral factor Xa inhibitor, Arteriosclerosis, Thrombosis, and Vascular Biology 30 (2010) 376-381. Go to original source... Go to PubMed...
    20. C. Weinz, T. Schwarz, D. Kubitza, et al., Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans, Drug Metabolism and Disposition 37 (2009) 1056-1064. Go to original source... Go to PubMed...
    21. M.R. Patel, K.W. Mahaffey, J. Garg, et al., ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, The New England Journal of Medicine 365 (2011) 883-891. Go to original source... Go to PubMed...
    22. G.J. Hankey, M.R. Patel, S.R. Stevens, et al., Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: a subgroup analysis of ROCKET AF, Lancet Neurology 11 (2012) 315-322. Go to original source... Go to PubMed...
    23. P.C. Wong, D.J. Pinto, D. Zhang, et al., Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor, Journal of Thrombosis and Thrombolysis 31 (2011) 478-492. Go to original source... Go to PubMed...
    24. N. Raghavan, C.E. Frost, Z. Yu, et al., Apixaban metabolism and pharmacokinetics after oral administration to humans, Drug Metabolism and Disposition 37 (2009) 74-81. Go to original source... Go to PubMed...
    25. C.B. Granger, J.H. Alexander, J.J. McMurray, et al., ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation, The New England Journal of Medicine 365 (2011) 981-992. Go to original source... Go to PubMed...
    26. R.D. Lopes, S.M. Al-Khatib, L. Wallentin, et al., Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial, Lancet 380 (2012) 1749-1758. Go to original source... Go to PubMed...
    27. S.H. Hohnloser, Z. Hijazi, L. Thomas, et al., Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial, European Heart Journal 33 (2012) 2821-2830. Go to original source... Go to PubMed...
    28. M. Tendera, M. Syzdol, Z. Parma, ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?, Cardiology Journal 1 (2012) 4-10. Go to original source... Go to PubMed...
    29. A.J. Camm, G.Y.H. Lipp, R. De Caterina, et al., 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association, European Heart Journal 33 (2012) 2719-2747. Go to original source... Go to PubMed...
    30. P. Pruszczyk, J. Stepinska, W. Banasiak, et al., New oral anticoagulants in the prevention of embolic complications in patients with atrial fibrillation. Polish Cardiac Society, Polish Neurological Society and Working Group on Haemostasis of the Polish Society of Haematologists and Transfusiologists consensus statement, Kardiologia Polska 70 (2012) 979-988. Go to PubMed...
    31. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, et al., Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects, Circulation 124 (2011) 1573-1579. Go to original source... Go to PubMed...
    32. R. Marlu, E. Hodaj, A. Paris, et al., Effect of nonspecific reversal agents on anticoagulant activity of dabigatran, rivaroxaban. A randomized crossover ex vivo study in healthy volunteers, Thrombosis and Haemostasis 108 (2012) 217-224. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes